Key result
Pravastatin has been proposed for preventing preeclampsia in high-risk women, but a large randomized-controlled trial is needed before it becomes part of routine clinical practice.
Why the study?
Does adding pravastatin to aspirin prevent preeclampsia in high-risk pregnant women?
Does adding pravastatin to aspirin prevent preeclampsia in high-risk pregnant women?
A large randomized controlled trial is required to determine if adding pravastatin to aspirin is effective and safe for preventing preeclampsia in high-risk women.
Preeclampsia is a multisystem disorder that affects 3% to 5% of pregnant women and remains a significant source of short-term and long-term maternal and neonatal mortality and morbidity. Many professional societies recommend the use of low-dose aspirin to prevent preeclampsia in high-risk women. Owing to the similarities in pathophysiology between preeclampsia and atherosclerotic cardiovascular disease, and the encouraging data from preclinical and pilot clinical studies, pravastatin has been proposed for preventing preeclampsia. However, before statin administration becomes part of routine clinical practice, a large, well-designed, and adequately powered randomized-controlled trial is needed.
No takes yet. Share an insight, caveat, or question.
Marrs et al. (2016) conducted an editorial in Preeclampsia. Pravastatin was evaluated. Pravastatin has been proposed for preventing preeclampsia in high-risk women, but a large randomized-controlled trial is needed before it becomes part of routine clinical practice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: